Baseline cost-effectiveness results
| Strategy | Comparison with common baseline (no screening) | Sequential ICER, $ | ||||
|---|---|---|---|---|---|---|
| Cost,* $ | QALYs | ΔCost, $ | ΔQALYs | ICER, $ | ||
| Age 25–64 yr | ||||||
| No screening | 71 327 | 13.7653 | – | – | – | – |
| Screen and treat with PEG IFN+RBV | 71 450 | 13.7685 | 124 | 0.0032 | 38 117† | 38 117† |
| Screen and treat with interferon-free DAA (G1), SOF+RBV (G2/3) or PEG IFN+RBV (G4/5/6) | 71 593 | 13.7729 | 266 | 0.0077 | 34783 | 34783 |
| Screen and treat with simeprevir+PEG IFN+RBV (G1), SOF+RBV (G2/3) or PEG IFN+RBV (G4/5/6) | 71 593 | 13.7716 | 267 | 0.0063 | 42398 | Dominated |
| Age 45–64 yr | ||||||
| No screening | 83 335 | 12.1027 | – | – | – | – |
| Screen and treat with PEG IFN+RBV | 83 476 | 12.1068 | 141 | 0.0041 | 34359 | 34359 |
| Screen and treat with simeprevir+PEG IFN+RBV (G1), SOF+RBV (G2/3) or PEG IFN+RBV (G4/5/6) | 83 672 | 12.1104 | 337 | 0.0077 | 44034 | 55 151† |
| Screen and treat with interferon-free DAA (G1), SOF+RBV (G2/3) or PEG IFN+RBV (G4/5/6) | 83 673 | 12.1122 | 338 | 0.0095 | 35562 | 36471 |
Note: Δ = change; DAA = direct-acting antiviral agent; G1 = genotype 1; G2/3 = genotype 2 or 3; G4/5/6 = genotype 4, 5 or 6; ICER = incremental cost-effectiveness ratio; PEG IFN+RBV = pegylated interferon plus ribavirin; QALY = quality-adjusted life-year; SOF+RBV = sofosbuvir plus ribavirin.
↵* Within each age group, options are ordered by exact cost; here, costs are presented to the nearest dollar.
↵† Extended dominance, i.e., the combination of 2 other alternatives dominated the treatment. In cost-effectiveness analyses, extended dominance rules out any intervention that has an ICER greater than that of a more effective intervention.